ClinicalTrials.gg
Active, not recruitingNCT05208086RHUMMUpdated Apr 13, 2026

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

An observational study in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Active, not recruiting at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Intergroupe Francophone du Myelome · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome — 1 open to participants now, 4 under way, 2 of them phase 3. Multiple Myeloma · Intergroupe Francophone du Myelome.

Started
2022
the only one that year
Observational
3 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, this one is the only one that started in 2022, is one of 3 observational ones, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.

Read the detailed description

To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients.

180 evaluable patients are required. For each of them, both spot urine sample and 24h urine sample will be collected at Cycle1 Day1, Cycle 2 Day 1 and Cycle 4 Day 1.

The detection of urine monoclonal component will be performed by urine protein electrophoresis (quantitative) and urine immunofixation (qualitative).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Monoclonal components detection
  • Urine sample
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with Multiple Myeloma whatever the line of treatment started in one of the twenty investigators sites located in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with Multiple Myeloma
  • Patient starting new treatment line, whatever the line is, but with at least 3 induction cycles
  • Urine monoclonal component ≥ 200mg/24h

Exclusion criteria

Exclusion Criteria:

Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    Cycle1 day1: collection of 24h urine and an urine sample from miction the day of the visit. Cycle 2 day1:collection of 24h urine and an urine sample from miction the day of the visit Cycle 4 day 1: collection of 24h urine and an urine sample from miction the day of the visit.

    Diagnostic Test: Detection of monoclonal component

Interventions

  • Diagnostic testDetection of monoclonal component

    Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.

06

What researchers measure

Primary outcomes

  1. Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample

    Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample compared to the reference measurement of 24 hours urine. Sensitivity is defined as the proportion, among the patients with positive urinalysis results on 24 hours urine, of positive results on spot urine sample. Evaluation is performed by urine protein electrophoresis and urine immunofixation

    Time frame: at the first Day of Cycle n°2 (each cycle is 28 days or 21 days)

Secondary outcomes

  1. Evaluate the specificity of urine monoclonal component detection on spot urine sample

    Evaluate the specificity of urine monoclonal component detection on sample at C2D1 compared to the reference measurement of 24 hours urine sample. Specificity is defined as the proportion, among patients with negative urinalysis results on 24 hours urine, of negative results on the spot urine sample.

    Time frame: at the first Day of cycle n°2 (each cycle is 28 days or 21 days)

  2. Evaluate the sensitivity and specificity of urine monoclonal component detection on spot urine sample

    Evaluate the sensitivity and specificity of urine monoclonal component detection on spot urine sample at C1D1 and C4D1 compared to reference measurement of 24hours urine sample

    Time frame: at the first day of cycle n°1 and cycle n°4 (each cycle is 28 days or 21 days)

  3. Compare the responses rate

    Compare the rate of partial responses, very good partial responses and complete responses (IMWG criteria) but only on the urinary monoclonal component) at C2D1 and C4D1 between the two types of samples (spot urine sample and 24hours urine sample)

    Time frame: at the first day of cycle n° 2 and cycle 4 (each cycle is 28 days or 21 days)

  4. Compare the monoclonal component / creatininuria ratios

    Compare the monoclonal component / creatininuria ratios in both samples (spot urine sample and 24hours urine sample) for components monoclonal which are quantifiable in both types of urine samples

    Time frame: at the first day of cycle n° 1,2 and 4

  5. Define the equivalent of 200 mg / 24H (current consensus threshold of measurable urinary disease)

    Define the equivalent of 200 mg / 24H (current consensus threshold of measurable urinary disease) at C1D1 and on the others points, if the monoclonal component is quantifiable)

    Time frame: at the first day of cycle n° 1 (each cycle is 28 days or 21 days)

  6. Assess the association between the rate of serum light chains and concentration of monoclonal components

    To assess the association between serum light chains and concentration of monoclonal components for both types of urine samples.

    Time frame: at first day of cycle 2 (each cycle is 28 days or 21 days)

  7. Evaluate the urine monoclonal component by the difference between proteinuria and albuminuria

    To Evaluate if the rate of urine monoclonal component (in g/L)could by calculated by the difference between proteinuria (in g/L) and albuminuria (in g/L)

    Time frame: at first day of cycle 2 (each cycle is 28 days or 21 days)

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2026, 48 months after the start.

Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 33. This study's planned 48 months is below that.

Counting every sponsor, half of 239 studies reached it within 61 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Jan 26, 2022
StartActual
May 18, 2022
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05208086
Lead sponsor
Intergroupe Francophone du Myelome
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
May 18, 2022
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Olivier DECAUX, PU-PH
principal investigator · Rennes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion